On Tuesday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was -1.86% drop from the session before settling in for the closing price of $13.47. A 52-week range for DAWN has been $11.51 – $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 68.09%. With a float of $68.40 million, this company’s outstanding shares have now reached $100.81 million.
The firm has a total of 155 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.37%, operating margin of -206.27%, and the pretax margin is -81.57%.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Day One Biopharmaceuticals Inc stocks. The insider ownership of Day One Biopharmaceuticals Inc is 32.17%, while institutional ownership is 81.48%. The most recent insider transaction that took place on Nov 18 ’24, was worth 139,420. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 10,554 shares at a rate of $13.21, taking the stock ownership to the 108,377 shares. Before that another transaction happened on Nov 18 ’24, when Company’s HEAD OF R&D sold 2,206 for $13.21, making the entire transaction worth $29,142. This insider now owns 1,064,015 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.09% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
You can see what Day One Biopharmaceuticals Inc (DAWN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Analysing the last 5-days average volume posted by the [Day One Biopharmaceuticals Inc, DAWN], we can find that recorded value of 1.33 million was better than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 25.33%. Additionally, its Average True Range was 0.63.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 16.31%, which indicates a significant increase from 6.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.98% in the past 14 days, which was lower than the 41.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.25, while its 200-day Moving Average is $14.53. Now, the first resistance to watch is $13.44. This is followed by the second major resistance level at $13.65. The third major resistance level sits at $13.81. If the price goes on to break the first support level at $13.07, it is likely to go to the next support level at $12.91. Should the price break the second support level, the third support level stands at $12.70.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are 100,846K outstanding shares of the company, which has a market capitalization of 1.33 billion. As of now, sales total 0 K while income totals -188,920 K. Its latest quarter income was 93,760 K while its last quarter net income were 37,040 K.
